Overview
ELTX market data
Price History
ELTX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.33 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.32 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -81.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.66 – $16.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $72.7M · P/B 85.10 · P/S 2.45.
Company News
Elicio Therapeutics Q2 EPS $(0.43) Beats $(0.54) EstimateBenzinga · Aug 13, 2026, 8:18 PM
8-K filing — Elicio Therapeutics, Inc. (ELTX)SEC EDGAR · Aug 13, 2026, 8:06 PM
Elicio Therapeutics Announces Opening Of 20-Patient Investigator-Initiated Phase 1 Trial Of ELI-002 7P With Chemotherapy, Anti-PD1 In Neoadjuvant Pancreatic Cancer At Memorial Sloan KetteringBenzinga · Aug 10, 2026, 12:06 PM
Elicio Therapeutics Added to Russell 2000® and Russell 3000® IndexesGlobenewswire Inc · Jun 29, 2026, 12:15 PM
Elicio Therapeutics Added To Russell 2000, 3000 Indexes, Effective June 26Benzinga · Jun 29, 2026, 12:10 PM
Ladenburg Thalmann Assumes Elicio Therapeutics at Buy, Announces Price Target of $12Benzinga · Jun 18, 2026, 7:10 PM
Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer DrugBenzinga · Jun 17, 2026, 4:50 PM
Elicio Therapeutics Reports 100% Complete Responses In Three Metastatic Pancreatic Cancer Patients Following ELI-002 7P And Nivolumab TherapyBenzinga · Jun 17, 2026, 12:25 PM
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment And Subsequent Therapy With Checkpoint InhibitionBenzinga · Jun 17, 2026, 12:10 PM
Jones Trading Downgrades Elicio Therapeutics to HoldBenzinga · Jun 16, 2026, 4:35 PM